Imperatorin acts as a cisplatin sensitizer via downregulating Mcl-1 expression in HCC chemotherapy

Tumor Biology

Volumn 37, Issue 1, 2016, Pages 331-339

  Hu, Jianjian ^a   Xu, Changlong ^a   Cheng, Bihuan ^a   Jin, Lingxiang ^a   Li, Jie ^a   Gong, Yuqiang ^a   Lin, Wei ^a   Pan, Zhenzhen ^b   Pan, Chenwei ^a  

^a THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cisplatin; HCC; Imperatorin; Mcl 1

Indexed keywords

CISPLATIN; MESSENGER RNA; PENTOSALEN; PROTEIN MCL 1; ANTINEOPLASTIC AGENT; FUROCOUMARIN DERIVATIVE; MCL1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; MCL 1 GENE; MITOCHONDRIAL MEMBRANE POTENTIAL; MTT ASSAY; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; HEP-G2 CELL LINE; LIVER TUMOR; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FUROCOUMARINS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PLASMIDS; POLYMERASE CHAIN REACTION;

EID: 84938151259     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3591-z     Document Type: Article

References (33)

1. Li W, Xie L, He X, Li J, Tu K, Wei L, et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer. 2008;123:1616–22.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
3. Kerr SH, Kerr DJ. Novel treatments for hepatocellular cancer. Cancer Lett. 2009;286:114–20.
4. Hubaux R, Thu KL, Vucic EA, Pikor LA, Kung SH, Martinez VD, et al. Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in non-small cell lung cancer. Int J Cancer. 2015.
5. Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, et al. Systems biology ofcisplatin resistance: past, present and future. Cell Death Dis. 2014;5:e1257.
6. O’Grady S, Finn SP, Cuffe S, Richard DJ, O’Byrne KJ, Barr MP. The role of DNA repair pathways in cisplatin resistant lung cancer. Cancer Treat Rev. 2014;40:1161–70.
7. Rytelewski M, Tong JG, Koropatnick J, et al. BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis. Mol Oncol. 2014;8:1429–40.
8. Rahman A, Siddiqui SA, Jakhar R, Kang SC. Growth inhibition of various human cancer cell lines by imperatorin and limonin from poncirus trifoliata rafin. Seeds Anticancer Agents Med Chem. 2015;15:236–41.
9. García-Argáez AN, Ramírez Apan TO, Parra Delgado H, Velázquez G, Martínez-Vázquez M. Anti-inflammatory activity of coumarins from Decatropis bicolor on TPA ear mice model. Planta Med. 2000;66:279–81.
10. Zhang Y, Cao Y, Zhan Y, Duan H, He L. Furanocoumarins-imperatorin inhibits myocardial hypertrophy both in vitro and in vivo. Fitoterapia. 2010;81:1188–95.
11. Choochuay K, Chunhacha P, Pongrakhananon V, Luechapudiporn R, Chanvorachote P. Imperatorin sensitizes anoikis and inhibits anchorage-independent growth of lung cancer cells. J Nat Med. 2013;67:599–606.
12. Luo KW, Sun JG, Chan JY, Yang L, Wu SH, Fung KP, et al. Anticancer effects of imperatorin isolated from Angelica dahurica: induction of apoptosis in HepG2 cells through both death-receptor- and mitochondria-mediated pathways. Chemotherapy. 2011;57:449–59.
13. Bądziul D, Jakubowicz-Gil J, Paduch R, Głowniak K, Gawron A. Combined treatment with quercetin and imperatorin as a potent strategy for killing HeLa and Hep-2 cells. Mol Cell Biochem. 2014;392:213–27.
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2011;25:402–8.
15. Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 2011;18:1414–24.
16. Varadarajan S, Butterworth M, Wei J, Pellecchia M, Dinsdale D, Cohen GM. Sabutoclax (BI97C1) and BI112D1, putative inhibitors of MCL-1, induce mitochondrial fragmentation either upstream of or independent of apoptosis. Neoplasia. 2013;15:568–78.
17. Zhang Z, Zheng L, Zhao Z, Shi J, Wang X, Huang J. Grape seed proanthocyanidins inhibit H2O2-induced osteoblastic MC3T3-E1 cell apoptosis via ameliorating H2O2-induced mitochondrial dysfunction. J Toxicol Sci. 2014;39:803–13.
18. Prathapan A, Vineetha VP, Raghu KG. Protective effect of Boerhaavia diffusa L. against mitochondrial dysfunction in angiotensin II induced hypertrophy in H9c2 cardiomyoblast cells. PLoS One. 2014;9, e96220.
19. Colombo F, Trombetta E, Cetrangolo P, Maggioni M, Razini P, De Santis F, et al. Giant lysosomes as a chemotherapy resistance mechanism in hepatocellular carcinoma cells. PLoS One. 2014;9:e114787.
20. Wang B, Ni Z, Dai X, Qin L, Li X, Xu L, et al. The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells. Mol Cancer. 2014;13:98.
21. Wang B, Chen L, Ni Z, Dai X, Qin L, Wu Y, et al. Hsp90 inhibitor 17-AAG sensitizes Bcl-2 inhibitor (−)-gossypol by suppressing ERK-mediated protective autophagy and Mcl-1 accumulation in hepatocellular carcinoma cells. Exp Cell Res. 2014;328:379–87.
22. Leuenroth SJ, Grutkoski PS, Ayala A, Simms HH. The loss of Mcl-1 expression in human polymorphonuclear leukocytes promotes apoptosis. J Leukoc Biol. 2000;68:158–66.
23. Thomas L, Lam C, Edwards S. Mcl-1 the molecular regulation of protein function. FEBS Lett. 2010;584:2981–9.
24. Sieghart W, Losert D, Wacheck V, et al. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol. 2006;44:151–7.
25. Sieghart W, Losert D, Wacheck V, et al. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol. 2006;44:151–7.
26. Williams MM, Cook RS. Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance? Oncotarget. 2015;6:3519–30.
27. Wei S, Dong K, Lin F, Wang X, Li B, Shen J, et al. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting mcl-1 gene in pancreatic carcinoma cell. Cancer Chemother Pharmacol. 2008;62:1055–64.
28. Zhang R, Li Y, Dong X, Peng L, Nie X. MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer. Med Oncol. 2014;31:347.
29. Pae HO, Oh H, Yun YG, Oh GS, Jang SI, Hwang KM, et al. Imperatorin, a furanocoumarin from Angelica dahurica (Umbelliferae), induces cytochrome c-dependent apoptosis in human promyelocytic leukaemia, HL-60 cells. Pharmacol Toxicol. 2002;91:40–8.
30. Bądziul D, Jakubowicz-Gil J, Langner E, Rzeski W, Głowniak K, Gawron A. The effect of quercetin and imperatorin on programmed cell death induction in T98G cells in vitro. Pharmacol Rep. 2014;66:292–300.
31. Ziko L, Riad S, Amer M, Zdero R, Bougherara H, Amleh A. Mechanical stress promotes Cisplatin-induced hepatocellular carcinoma cell death. Biomed Res Int. 2015;2015:430569.
32. Xie X, Hu Y, Xu L, Fu Y, Tu J, Zhao H, et al. The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer. Tumour Biol. 2015.
33. Zhao J, Li X, Zou M, He J, Han Y, Wu D, et al. miR-135a inhibition protects A549 cells from LPS-induced apoptosis by targeting Bcl-2. Biochem Biophys Res Commun. 2014;452:951–7.